The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.
Abstract
Myocardial infarction is the most frequent cause of mortality in the United States as well as in most western countries. In this review, the processes leading to myocardial infarction are described based on the most recent studies of vascular biology; in addition, evolving strategies for prevention are outlined. The following was specifically discussed. (1) Five phases of the progression of coronary atherosclerosis (phases 1 to 5) and eight morphologically different lesions (types I, II, III, IV, Va, Vb, Vc, and VI) in the various phases are defined. (2) The present understanding of the pathogenesis of each of the phases of progression and of the various lesion types preceding myocardial infarction is described; particular emphasis is placed on the physical, structural, cellular, and chemical characteristics of the "vulnerable or unstable plaques" prone to disruption (types IV and Va lesions). (3) The fate of plaque disruption (type VI lesion) in the genesis of the various coronary syndromes and especially acute myocardial infarction is defined; particular emphasis is placed on the combination of plaque disruption and a high thrombogenic risk profile--local factors (ie, degree of plaque disruption, exposure of lipid-macrophage-rich plaque, etc) and systemic factors (ie, catecholamines, RAS, fibrinogen, etc)--in the genesis of myocardial infarction. (4) Strategies of regression or stabilization of "vulnerable or unstable plaques" for prevention of myocardial infarction are presented within the context of recent favorable experience with risk factor modification and lipid-modifying angiographic trials, beta-blockade and angiotensin-converting enzyme inhibition, antithrombotic strategies, and the possible role of estrogens. The recent past has been very fruitful in yielding a better understanding of the processes leading to myocardial infarction, and the near future appears very promising in terms of preventing the number 1 killer in the western world.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, therapies for lowering the concentration of homocysteine through vitamin supplementation did not result in the suppression of events292, 293).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [293]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y. I., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,716
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,618
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Vascular endothelial cells synthesize nitric oxide from L-arginine
Palmer, R. M. J., Ashton, D., & Moncada, S. (1988) · Nature · doi:10.1038/333664a0 · Cited by 4,786
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimón, L., Badimón, L., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,792
Self-citation(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Moncada, S., Gryglewski, R. J., Bunting, S., & Vane, J. R. (1976) · Nature · doi:10.1038/263663a0 · Cited by 3,593
Flagged first, then by citations
Cited by
Sorted by citations
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Self-citationMolecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease
Nygard, O. K., Nordrehaug, J. E., Refsum, H., Ueland, P. M., Farstad, M., & Vollset, S. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370403 · Cited by 1,746
Atherosclerosis: Basic Mechanisms
Berliner, J. A., Navab, M., Fogelman, A. M., Frank, J. S., Demer, L. L., Edwards, P. A., Watson, A. D., & Lusis, A. J. (1995) · Circulation · doi:10.1161/01.cir.91.9.2488 · Cited by 1,730
Metadata
- Authors
- Fuster, V
- Affiliations
- Mount Sinai Hospital (US)
- Corresponding author
- Fuster, V
- ORCID
- Fuster, V
- Venue
- Circulation
- Published
- 1994-10
- Volume
- 90
- Issue
- 4
- Pages
- 2126-2146
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2110185147
- Cited by
- 848
- References
- 240
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 7 · 2023: 11 · 2022: 9 · 2021: 4 · 2020: 14 · 2019: 6 · 2018: 5 · 2017: 12 · 2016: 19 · 2015: 16 · 2014: 19 · 2013: 24 · 2012: 18
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- myocardial infarction, coronary artery disease, vulnerable plaque, plaque disruption, lesion type, plaque regression, thrombosis, coronary syndrome, risk factor control, lipid therapy, beta-adrenergic blockade, angiotensin-converting enzyme inhibition, antithrombotic therapy, estrogen, vascular biology
- MeSH terms
- Coronary Artery Disease, Coronary Thrombosis, Coronary Vessels, Humans, Myocardial Infarction, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
